

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 22, 2024**

**Abacus Life, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation  
or organization)

**001-39403**  
(Commission  
File Number)

**85-1210472**  
(I.R.S. Employer  
Identification Number)

**2101 Park Center Drive, Suite 200  
Orlando, Florida 32835  
(800) 561-4148**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbols	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	ABL	The NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of \$11.50 per share	ABLLW	The NASDAQ Stock Market LLC
9.875% Fixed Rate Senior Notes due 2028	ABLLL	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 2.02. Results of Operations and Financial Condition

On October 22, 2024, Abacus Life, Inc. (Abacus or Company) issued a press release announcing preliminary financial results for the quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” with the U.S. Securities and Exchange Commission or otherwise incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

## Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	<a href="#">Press Release, dated October 22, 2024, announcing preliminary financial results for the quarter ended September 30 2024.</a>
104	Cover Page Interactive Data File (formatted as inline XBRL).

## Forward Looking Statements

This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Abacus’ public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Abacus’ most recent annual report on Form 10-K, as amended, and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Abacus’ other filings with the SEC, including those contained in the final prospectus and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements represent Abacus’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Abacus explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Abacus Life, Inc.**

(Registrant)

Date: October 22, 2024

By: /s/ Jay Jackson  
Name: Jay Jackson  
Title: Chief Executive Officer

## ABACUS LIFE PROVIDES PRELIMINARY THIRD QUARTER 2024 RESULTS

*- Expects Total Revenue Between \$26.0 and \$28.0 Million; Grows 23-33% Year-over-Year -*

*- Expects GAAP Net Income / (Loss) Between (\$6.0) and (\$6.75) Million Due to Non-Cash Increase in Warrant Liability of Between \$8.0 and \$9.0 Million -*

*- Expects Adjusted EBITDA Between \$14.0 and \$16.0 Million; Grows 30-48% Year-over-Year -*

*- Third Quarter 2024 Earnings Release and Conference Call to be Held Thursday, November 7, 2024 -*

**ORLANDO, Fla. – October 22, 2024** – Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan based financial products, today announced preliminary unaudited financial results for the third quarter ended September 30, 2024.

### Preliminary Financial Results - Third Quarter 2024

Based upon management's current expectations, the Company anticipates Total Revenue, Net Income, and Adjusted EBITDA, for the third quarter as follows:

	<b>3Q24</b>
Total Revenue	Between \$26.0 and \$28.0 million
GAAP Net Income / (Loss)	Between (\$6.0) and (\$6.75) million
Adjusted EBITDA	Between \$14.0 and \$16.0 million

“We are pleased to report another strong performance across our business, continuing to underscore the clear differentiation of our business model,” said Jay Jackson, Chief Executive Officer of Abacus. “During the quarter, we announced key acquisitions of Carlisle Management Company SCA and FCF Advisors. We are excited to welcome them to the Abacus family. In addition, we further strengthened our management team, welcoming Corey McLaren as Managing Director of Capital Markets and Robert F. Phillips as our new Senior Vice President of Investor Relations and Corporate Affairs. We also partnered with Lorisco to launch PREADISAN™, a revolutionary health prediction and actuarial technology tool, which is enabling us to offer unprecedented personalization in longevity forecasting, as well as highly tailored financial solutions for our clients. We remain committed to executing on our long-term growth initiatives and delivering value to our shareholders.”

### Earnings Release and Conference Call

As previously noted, Abacus Life, Inc. will release its third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Management will hold a conference call to discuss the financial results at 5:00 pm Eastern Time on November 7, 2024. A live webcast of the conference call will be available on Abacus’ investor relations website at [ir.abaculuslife.com](http://ir.abaculuslife.com). The dial-in number for the conference call is (800) 267-6316 (toll-free) or (203) 518-9783 (international). Please dial the number 10 minutes prior to the scheduled start time.

### Preliminary Information

The unaudited financial and operational information presented in this press release is preliminary and may change. Abacus’ financial closing procedures with respect to the estimated financial information provided in this press release are not yet complete, and as a result, the Company’s final results may vary materially from the preliminary results included in this press release. Abacus undertakes no obligation to update or supplement the information provided in this

press release until the Company releases its financial statements for the three months ended September 30, 2024. The preliminary financial information included in this press release reflects the Company's current estimates based on information available as of the date of this press release and has been prepared by Company management. This preliminary financial and operational information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and is not necessarily indicative of the results to be achieved for any future periods. This preliminary financial information could be impacted by the effects of financial closing procedures, final adjustments, and other developments.

### **Non-GAAP Financial Information**

Adjusted EBITDA, a non-GAAP measure, is defined as net income (loss) attributable to Abacus adjusted for depreciation expense, amortization, interest expense, income tax and other non-cash and certain non-recurring items that in our judgement significantly impact the period-over-period assessment of performance and operating results that do not directly relate to business performance within Abacus' control. A reconciliation of Adjusted EBITDA to Net income attributable to Abacus Life, the most directly comparable GAAP measure, appears below.

### **Forward-Looking Statements**

All statements in this press release (and oral statements made regarding the subjects of this press release) other than historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Abacus. Forward-looking information includes but is not limited to statements regarding: Abacus's financial and operational outlook; Abacus's operational and financial strategies, including planned growth initiatives and the benefits thereof, Abacus's ability to successfully effect those strategies, and the expected results therefrom. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "expect," "intend," "anticipate," "goals," "prospects," "will," "would," "will continue," "will likely result," and similar expressions (including the negative versions of such words or expressions).

While Abacus believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward-looking statements include, but are not limited to: the fact that Abacus's loss reserves are based on estimates and may be inadequate to cover its actual losses; the failure to properly price Abacus's insurance policies; the geographic concentration of Abacus's business; the cyclical nature of Abacus's industry; the impact of regulation on Abacus's business; the effects of competition on Abacus's business; the failure of Abacus's relationships with independent agencies; the failure to meet Abacus's investment objectives; the inability to raise capital on favorable terms or at all; the effects of acts of terrorism; and the effectiveness of Abacus's control environment, including the identification of control deficiencies.

These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties set forth in documents filed by Abacus with the U.S. Securities and Exchange Commission from time to time, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and subsequent periodic reports. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Abacus cautions you not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus does not give any assurance that it will achieve its expectations.

## **About Abacus**

Abacus is a leading global alternative asset manager and market maker, specializing in use of advanced longevity and actuarial technology to purchase life insurance policies from consumers seeking liquidity while creating a high-returning asset class of insurance products, uncorrelated to market fluctuations, for institutional investors.

With nearly \$3 billion in assets under management, including pending acquisitions, Abacus is the only publicly traded global alternative asset manager focused on lifespan-based financial products traded on the Nasdaq exchange.

Abacus has invested in two new verticals: ABL Wealth, which provides longevity-based wealth management services and investment offerings, and ABL Tech, which offers ground-breaking technology services for pension funds, governments, insurance companies, retirement associations and more that provides advanced real-time data tracking and analysis. With each new channel, we are revolutionizing the future of life insurance.

[www.Abacuslife.com](http://www.Abacuslife.com)

### Contacts:

#### **Investor Relations**

Robert Phillips – SVP Investor Relations  
[rob@abacuslife.com](mailto:rob@abacuslife.com)  
(321) 290-1198

David Jackson – IR/Capital Markets Associate  
[djackson@abacuslife.com](mailto:djackson@abacuslife.com)  
(321) 299-0716

#### **Abacus Life Public Relations**

[press@abacuslife.com](mailto:press@abacuslife.com)

**ABACUS LIFE, INC. Adjusted EBITDA**

	<b>Three Months Ended September 30, 2024</b>		<b>Three Months Ended September 30, 2023</b>
	<b>Low</b>	<b>High</b>	<b>Actual</b>
<b>Net income attributable to Abacus Life, Inc.</b>	<b>\$ (6,750,000)</b>	<b>\$ (6,000,000)</b>	<b>\$ 1,050,972</b>
Net income	(6,750,000)	(6,000,000)	1,050,972
Depreciation and amortization expense	1,675,000	1,750,000	1,694,853
Income tax (benefit)	(550,000)	(400,000)	1,710,315
Stock-based compensation	6,300,000	6,500,000	4,583,632
Due Diligence related to acquisitions	1,725,000	2,000,000	-
Other (expense)	-	25,000	(20,086)
Interest expense	3,900,000	4,125,000	2,679,237
Interest income	(600,000)	(650,000)	(63,826)
(Gain) Loss on change in fair value of debt	-	150,000	(2,088,797)
Change in fair value of warrant liability	8,750,000	8,900,000	943,400
Realized & Unrealized (gain) on investments	(450,000)	(400,000)	306,800
<b>Adjusted EBITDA</b>	<b>\$ 14,000,000</b>	<b>\$ 16,000,000</b>	<b>\$ 10,796,500</b>